Vasomune Therapeutics, Inc.
Vasomune Therapeutics is a private biotechnology company focused on developing next-generation medicines that improve the body's ability to defend against illness by targeting vascular endothelial dysfunction. Their lead drug candidate AV-001 is designed to stabilize vasculature, reduce vascular leak, and treat diseases such as ARDS, COVID-19, sepsis, and other conditions related to vascular dysfunction. The company emphasizes a novel therapeutic approach that activates the Tie2 receptor to promote vascular stability and integrity.
Industries
Nr. of Employees
small (1-50)
Vasomune Therapeutics, Inc.
Patents
Products
AV-001 (PEGylated angiopoietin-1 mimetic peptide)
Investigational, fully synthetic PEGylated peptide therapeutic designed to activate the Tie2 receptor on endothelial cells to enhance vascular barrier integrity, reduce vascular leak and counteract vascular inflammation for indications driven by endothelial dysfunction.
AV-001 (PEGylated angiopoietin-1 mimetic peptide)
Investigational, fully synthetic PEGylated peptide therapeutic designed to activate the Tie2 receptor on endothelial cells to enhance vascular barrier integrity, reduce vascular leak and counteract vascular inflammation for indications driven by endothelial dysfunction.
Services
End-to-end clinical development services including Phase 1 safety/PK studies and Phase 2a proof-of-concept trials conducted under co-development agreements and site networks across multiple countries.
Design and execution of preclinical studies in multiple animal models to evaluate vascular barrier stabilization, survival, and organ protection endpoints for candidate therapeutics targeting endothelial function.
End-to-end clinical development services including Phase 1 safety/PK studies and Phase 2a proof-of-concept trials conducted under co-development agreements and site networks across multiple countries.
Design and execution of preclinical studies in multiple animal models to evaluate vascular barrier stabilization, survival, and organ protection endpoints for candidate therapeutics targeting endothelial function.
Expertise Areas
- Vascular-targeted therapeutics
- Peptide drug design and PEGylation
- Preclinical in vivo disease models (ARDS, pneumonia, sepsis, AKI, hemorrhagic shock)
- Clinical trial management (Phase 1–2a)
Key Technologies
- PEGylated peptide therapeutics
- Receptor agonist biologics (Tie2 pathway activation)
- In vivo animal models of respiratory infection and sepsis
- Pharmacokinetic (PK) analysis
News & Updates
Vasomune Therapeutics has received FDA Fast Track designation for AV-001, a novel investigational medicine targeting vascular dysfunction, to treat severe COVID-19 and related conditions.
Vasomune's lead drug candidate AV-001 will be presented at the 2024 Respiratory Innovation Summit, highlighting its potential in treating diseases related to vascular dysfunction.
Vasomune and AnGes announced that AV-001 received a positive recommendation from the IDSMB for its Phase 2a clinical study.
The first patient has been dosed in a Phase 2a clinical trial of AV-001 for severe COVID-19, aiming to evaluate its safety and efficacy.
Vasomune's Phase 1 trial of AV-001 showed it was safe and well-tolerated, supporting further development in COVID-19 patients.
Vasomune received FDA Fast Track designation for AV-001, supporting its development for COVID-19 and related vascular conditions.
Vasomune Therapeutics has received FDA Fast Track designation for AV-001, a novel investigational medicine targeting vascular dysfunction, to treat severe COVID-19 and related conditions.
Vasomune's lead drug candidate AV-001 will be presented at the 2024 Respiratory Innovation Summit, highlighting its potential in treating diseases related to vascular dysfunction.
Vasomune and AnGes announced that AV-001 received a positive recommendation from the IDSMB for its Phase 2a clinical study.
The first patient has been dosed in a Phase 2a clinical trial of AV-001 for severe COVID-19, aiming to evaluate its safety and efficacy.
Vasomune's Phase 1 trial of AV-001 showed it was safe and well-tolerated, supporting further development in COVID-19 patients.
Vasomune received FDA Fast Track designation for AV-001, supporting its development for COVID-19 and related vascular conditions.